U.S. PRODUCERS' QUESTIONNAIRE

GLYCINE FROM CHINA

This questionnaire must be received by the Commission by no later than April 27, 2011

See page 4 of the Instruction Booklet for filing instructions.

The information called for in this questionnaire is for use by the United States International Trade Commission in connection with its review of the antidumping duty order concerning glycine from China (Inv. No. 731-TA-718 (Third Review)). The information requested in the questionnaire is requested under the authority of the Tariff Act of 1930, title VII. This report is mandatory and failure to reply as directed can result in a subpoena or other order to compel the submission of records or information in your possession (19 U.S.C. § 1333(a)).

Name of firm													.
Address													
City			\$	State		Zip	Co Co	de					.
World Wide	Web add	ress											-
Has your firm J	produced g	lycine (as defin	ed in the ins	truction bool	klet)	at aı	ny tii	me sind	e Janu	ary 1,	2005	?	
□ NO	(Sign the ce	ertification below	and promptly	return only the	this pa	age o	of the	questio	nnaire t	o the C	ommi	ssion)	
☐ YES		nstruction bookle re to the Commis								turn th	e entiro	e	
			CERTI	FICATIO	N								
that the informat	tion herein	supplied in res				is co	omple	ete and	corre	ct to tl	ne bes	t of my	knov
that the informat ef and understand			ponse to thi	is questionne	aire i							t of my	knov
	d that the in cation I als this ques	nformation sub so grant conse tionnaire and	ponse to thi mitted is sub nt for the C throughout	is questionno bject to audi Commission, t this review	aire i it and , and	l ver l its	ifica emp	tion by ployees	the C	ommis ontra	sion. et per	sonnel,	to u
ef and understand ns of this certific tion provided in	that the interpretation I also this question on the transfer sees, and control this review programme.	nformation sub so grant conse tionnaire and e same or simile ubmitted in th ntract personna iew or related as and operatio	ponse to thi mitted is sul nt for the C throughout ur merchand is question el who are c proceedings ns of the Co	is questionno bject to audio Commission, t this review dise. naire respon acting in the for which t	aire i it and , and w in nse a e cap this i	l ver l its any and pacit infor	empy oth thro by of rmat	tion by ployees her im pughou Commi	the C and c port-in t this ission submit	ommis ontrac jury review emple ted, o	sion. ct per proce w ma oyees, r in ii	sonnel, edings y be u for dev	to u or re sed l velop audi
ef and understand ns of this certific tion provided in ed by the Commis wledge that info sion, its employed ning the records of ings relating to the	that the install that this question on the rmation sues, and confer this review programmen non-discontraction.	nformation sub so grant conse tionnaire and e same or simile ubmitted in th ntract personne iew or related j es and operatio closure agreem	ponse to thi mitted is sul nt for the C throughout ur merchand is question el who are c proceedings ns of the Co	is questionno bject to audio Commission, t this review dise. naire respon acting in the for which to ommission p	aire i it and , and w in nse a e cap this i	l verd l its any and pacit infor	empy oth thro by of rmat	tion by ployees her im pughou Commi	the C and c port-in t this ission submit	ommis ontrac jury review emple ted, o	sion. ct per proce w ma oyees, r in ii	sonnel, edings y be u for dev	to u or re sed l velop audi
ef and understand ns of this certific tion provided in ed by the Commis wledge that info sion, its employed ning the records of ings relating to the personnel will sig	that the install that this question on the rmation sues, and confer this review programmen non-discontraction.	nformation sub so grant conse tionnaire and e same or simile ubmitted in th ntract personne iew or related is and operatio closure agreem Title of Au	ponse to thi mitted is sult of the Control of the C	is questionno bject to audio Commission, t this review dise. naire respon acting in the for which to ommission p	aire i it and , and w in nse a e cap this i pursu	l verd l its any and pacit infor	empy oth thro ty of rmat to 5	tion by ployees her im oughou Comm ion is U.S.C	the C and c port-in t this ission submit	ommis ontrac jury review emple ted, o	sion. ct per proce w ma oyees, r in ii	sonnel, edings y be u for dev	to u or re sed l velop audi

PART I.—GENERAL INFORMATION

The questions in this questionnaire have been reviewed with market participants to ensure that issues of concern are adequately addressed and that data requests are sufficient, meaningful, and as limited as possible. Public reporting burden for this questionnaire is estimated to average 50 hours per response, including the time for reviewing instructions, searching existing data sources, gathering the data needed, and completing and reviewing the questionnaire. Send comments regarding the accuracy of this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Office of Investigations, U.S. International Trade Commission, 500 E Street, SW, Washington, DC 20436.

111111	or prepar	ing the re	pry to tills qu		mpleting the for hours		dollaı
ques	tionnaire	in general		in any comments y of specific questinddress.	•		
-	hlishmei	nts covere	edProvide	the name and addre			ed by this
ques	tionnaire	(see page	3 of the inst	ruction booklet for ock exchange and	1 00	, ·	•
ques publ	tionnaire icly trade	(see page ed, please s	3 of the instance of the stance of the stanc		trading symbol.	, •	r firm is

PART I.--GENERAL INFORMATION--Continued

☐ No	☐ YesList	the following information.	
Firm name		<u>Address</u>	Extent of owners
Related SUB		rs/exportersDoes vour fi	rm have any related firms, either
domestic or f	oreign, that are e		ne from China into the United Sta
☐ No	YesList	the following information.	
Firm name		Address	<u>Affiliation</u>
domestic or f	oreign, that are ed States or that	engaged in importing glyci	our firm have any related firms, eine from countries other than Chycine from countries other than Ch
☐ No	YesList	the following information.	
Firm name ar	nd country	Address	<u>Affiliation</u>

${\bf PART~I.-}\underline{\bf GENERAL~INFORMATION}\text{--}Continued$

Firm name	<u>Address</u>	<u>Affiliation</u>
		
luginaga nlan	In Doute II and IV of this questionneise w	
usiness plan.	In Parts II and IV of this questionnaire w Does your company or any related firm hat describe, discuss, or analyze expected ma	ve a business plan or any in
ousiness plan.	Does your company or any related firm ha	ve a business plan or any in rket conditions for glycine? cuments. If you are not proven
ousiness plan. locuments tha	Does your company or any related firm hat describe, discuss, or analyze expected ma	ve a business plan or any in rket conditions for glycine? cuments. If you are not proven
ousiness plan. documents tha	Does your company or any related firm hat describe, discuss, or analyze expected ma	ve a business plan or any in rket conditions for glycine? cuments. If you are not proven
business plan. documents tha	Does your company or any related firm hat describe, discuss, or analyze expected ma	ve a business plan or any in rket conditions for glycine? cuments. If you are not proven

PART II.—TRADE AND RELATED INFORMATION

Further information on this part of the questionnaire can be obtained from **Stefania Pozzi Porter** (202-205-3177, **Stefania.PozziPorter@usitc.gov**). Supply all data requested on a <u>calendar-year</u> basis.

II-1.	Please identify the individual to be copart II.	ontacted regarding the confidential information requested in
	Name and title:	
	Please indicate the manner by which part II with questions regarding the s	Commission staff may contact the individual responsible for ubmitted confidential information.
	E-mail:	Telephone: ()
	Fax: ()	
II-2.	<u>Changes in operations.</u> Please indichanges in relation to the production	cate whether your firm has experienced any of the following of glycine since January 1, 2005.
	(check as many as appropriate)	(please describe)
	plant openings	
	plant closings	
	relocations	
	expansions	
	acquisitions	
	consolidations	
	prolonged shutdowns or production curtailments	
	revised labor agreements	
	other (e.g., technology)	

PART II.—<u>TRADE AND RELATED INFORMATION</u>--Continued

□ No	YesSupply details as to the time, nature, and significance of such charand provide underlying assumptions, along with relevant portion business plans or other supporting documentation that address the issue. Include in your response a specific projection of your capacity to produce glycine (in 1,000 pounds) for 2011 and 2
	l changes in operations in the event the order is revokedWould your firm
anticipate a relating to t	I changes in operations in the event the order is revokedWould your firm many changes in the character of your operations or organization (as noted above) the production of glycine in the future if the antidumping duty order on glycine to be revoked?

PART II.—<u>TRADE AND RELATED INFORMATION</u>--Continued

pro	the following in duction capacity periods indicate	y and produ				
<u>Product</u>	<u>Period</u>				apacity and ate if differ	
Item	(Quantit	y in 1,000 po	ounds)	2008	2009	
Overall Production Capacity	2005	2000	2007	2000	2009	
Production of: Glycine						
Other product 1						
Other product 2						
production capacity.						
Production shiftingIs your in response to a relative chang the same equipment and/or lab	ge in the price of					

PART II.—TRADE AND RELATED INFORMATION -- Continued

II-8. <u>Trade data.</u>--Report your firm's production capacity, production, shipments, inventories, and employment related to the production of glycine in your U.S. establishment(s) during the specified periods. (See definitions in the instruction booklet.)

Quantity	(in 1,000 p	ounds) and	d value (in	\$1,000)		
				lar year		
Item	2005	2006	2007	2008	2009	2010
Average production capacity ¹ (quantity) (A)						
Beginning-of-period inventories (quantity) (B)						
Production (quantity) (C)						
U.S. shipments: Commercial shipments: quantity (D)						
value (E)						
Internal consumption: ² quantity (F)						
value (G)						
Transfers to related firms: ² quantity (H)						
value (I)						
Export shipments: ³ quantity (J)						
value (K)						
End-of-period inventories (quantity) (L)						
Channels of distribution: U.S. shipments to distributors (quantity) (M)						
U.S. shipments to end users (quantity) (N)						
Employment data: Average number of PRWs (number) (O)						
Hours worked by PRWs (1,000 hours) (P)						
Wages paid to PRWs (value) (Q)						
The production capacity (see of hours per week, weeks production capacity, and explain an necessary).	ber year. F	Please desc	ribe the me	thodology u	sed to calc	erating ulate
² Internal consumption and transevent that you use a different basis cost plus, <i>etc.</i>) and provide value date.	for valuing	these trans	actions, ple	ease specify	that basis	
³ Identify your principal export m	narkets:					

PART II.—TRADE AND RELATED INFORMATION -- Continued

II-9.	Recor	ciliation of trade data					
	(a)	Please note that the quantities reported in question II-8 should reconcile as follows in each period (<i>i.e.</i> , in each column):					
		$\frac{\text{Reconciliation}}{\text{B} + \text{C} - \text{D} - \text{F} - \text{H} - \text{J} = \text{L}}$	Do these data reconcile? Yes NoPlease explain				
		D + F + H = M + N	Do these data reconcile? Yes NoPlease explain				
	(b)	beginning-of-period inventori	reported for end-of-period inventories should equal the es reported in the subsequent calendar year (<i>i.e.</i> , line L of of year 2006). Do these data reconcile for each adjacent				
		Yes. NoP	lease explain.				
П-10.	indica wholly formu	te the nature of the relationship owned subsidiary), whether the	eported transfers to related firms in question II-8, please between your firm and the related firms (<i>e.g.</i> , joint venture e transfers were priced at market value or by a non-market narketing rights to all transfers, and whether the related ces other than your firm.				
II-11.	Please apply.	• •	ess your firm uses to produce glycine. (Check all that				
	anhyd	rous ammonia, sodium hydroxic	cess (This process uses formaldehyde, hydrogen cyanide le, and sulfuric acid as raw material inputs and/or catalysts is a distinct intermediate product in this process.)				
	anhyd inputs	rous ammonia, and hexamethyle	process (This process uses monochloroacetic acid, eneteramine (also known as hexamine) as raw material cine. Sodium glycinate is <u>not</u> an intermediate product in				
	<u> </u>	herPlease describe:					

PART II.—<u>TRADE AND RELATED INFORMATION</u>--Continued

II-12. <u>Purchases</u> Other 1, 2005? (See defined)				e purchased	glycine sir	ice January
□ No □		nte the reason se elaborate) elow for the	and report	the quantity		
Reasons:						
	(Quantity in 1,0			1		1
Item	2005	2006	2007	2008	2009	2010
PURCHASES FROM U.S. IMPORTERS¹ OF GLYCINE I China: quantity	FROM.—					
value						
All other countries: quantity						
value						
PURCHASES FROM DOMES PRODUCERS: ² quantity	STIC					
value						
PURCHASES FROM OTHER SOURCES: quantity						
Value						
1 Please list the name of the source, please identify the source. 2 Please list the name of the source.	urce for each listed su	ipplier.				iffer by
II-13. Toll production, definition in the ins	truction booklet) re	egarding the p	production	of glycine?		ment (see
□ No □	YesName firm(s)):				·
II-14. <u>FTZ</u> Does your fi	rm produce glycine	e in a foreign	trade zone	(FTZ)?		
□ No □	YesIdentify FTZ	(s):				

PART II.—TRADE AND RELATED INFORMATION--Continued

∐No	Yes <u>COMPLETE ANI</u> <u>QUESTIONNAL</u>	<u>D RETURN A U.S. IMPORTERS'</u> <u>RE</u>	
	ents by grade.—Please report the qua e (based on the actual quality of the g		
	U.S. Shi	pments	
	Product	Quantity (in 1,000 pounds)	-
	Pharmaceutical grade		-
	USP grade		- -
	Technical grade		1
	Other grade		
impor produ flow,	to of orderDescribe the significance ts of glycine from China in terms of it ction, U.S. shipments, inventories, pur capital expenditures, research and devo compare your firm's operations before	chases, employment, revenues, cost elopment expenditures, and asset va	apacity, ts, profits, cas alues. You m
impor produ flow,	ts of glycine from China in terms of it ction, U.S. shipments, inventories, pur capital expenditures, research and dev	s effect on your firm's production c chases, employment, revenues, cost elopment expenditures, and asset va	apacity, ts, profits, ca alues. You m
impor produ flow,	ts of glycine from China in terms of it ction, U.S. shipments, inventories, pur capital expenditures, research and dev	s effect on your firm's production c chases, employment, revenues, cost elopment expenditures, and asset va	apacity, ts, profits, cas alues. You m
Likel capac profits relating	ts of glycine from China in terms of it ction, U.S. shipments, inventories, pur capital expenditures, research and dev	s effect on your firm's production cachases, employment, revenues, cost elopment expenditures, and asset value and after the imposition of the or all your firm anticipate any changes tories, purchases, employment, revearch and development expenditures	apacity, ts, profits, cas alues. You m rder. s in its producenues, costs, s, or asset value
Likel capac profits relating	y effect of revocation of orderWould, production, U.S. shipments, inventories, purcapital expenditures, research and devo compare your firm's operations before the production, U.S. shipments, inventor, cash flow, capital expenditures, research and provide under the production of glycine in the firm the firm the production of glycine in the gl	s effect on your firm's production cochases, employment, revenues, cost elopment expenditures, and asset value and after the imposition of the order and after the imposition of the order and after the imposition of the order and development expenditures arch and development expenditures uture if the antidumping duty order to the time, nature, and significance or the time, nature, along with relevant of the supporting documentation for	apacity, ts, profits, car alues. You m rder. s in its producenues, costs, t, or asset value on glycine fr of such chang vant portions
Likel capac profit: relating	y effect of revocation of orderWould, y production, U.S. shipments, inventories, pur capital expenditures, research and devo compare your firm's operations before the production of orderWould, y production, U.S. shipments, invents, cash flow, capital expenditures, research and provide under the production of glycine in the firm of the production of glycine	s effect on your firm's production cochases, employment, revenues, cost elopment expenditures, and asset value and after the imposition of the order and after the imposition of the order and after the imposition of the order and development expenditures arch and development expenditures uture if the antidumping duty order to the time, nature, and significance or the time, nature, along with relevant of the supporting documentation for	apacity, ts, profits, car alues. You m rder. s in its producenues, costs, t, or asset value on glycine fr of such chang vant portions

PART III.—<u>FINANCIAL INFORMATION</u>

Address questions on this part of the questionnaire to Charles Yost (202-205-3432, Charles.Yost@usitc.gov).

III-1.	Please identify the individual to be contacted regarding the confidential information requested in part III?
	Name and title:
	Please indicate the manner by which Commission staff may contact the individual responsible for part III with questions regarding the submitted confidential information.
	E-mail: Telephone: ()
	Fax: ()
III-2.	General guidance:Financial data are requested on a product-line basis: the product is glycine, as defined in the instruction booklet. Inputs your firm receives from affiliates to produce glycine should be stated at cost (i.e., intra-firm profits eliminated, see question III-7) while transfers of glycine to related affiliates should be stated at fair market value. Please report all sales on an f.o.b. basis. Total sales in this section should equal total shipments plus exports in Part II, page 8 (trade data) of this questionnaire. PLEASE REPORT ALL FINANCIAL DATA ON A CALENDAR YEAR BASIS.
III-3.	Accounting systemBriefly describe your financial accounting system.
	 a) When does your fiscal year end (month and day)? b) Describe the lowest level of operations (e.g., plant, division, company-wide) for which financial statements are prepared that include subject merchandise: c) Does your firm prepare profit/loss statements for the subject merchandise: Yes No d) How often did your firm (or parent company) prepare financial statements (including annual reports, 10Ks)? Please check relevant items below. Audited, unaudited, annual reports, 10Ks, 10 Qs, Monthly, quarterly, semi-annually, annually
	e) Accounting basis: GAAP, cash, tax, or other comprehensive (specify)
profit-	The Commission may request that your company submit copies of its financial statements, including internal and-loss statements for the division or product group that includes glycine, as well as those statements and exects used to compile data for your firm's questionnaire response.
III-4.	<u>Cost accounting system</u> Briefly describe your cost accounting system (<i>e.g.</i> , standard cost, job order cost, <i>etc</i> .).

PART III.—<u>FINANCIAL INFORMATION</u>--Continued

produce	Other productsPlease list any other products you produced in the facilities in which you produced glycine, and provide the share of net sales accounted for by these other products in you most recent fiscal year:						
Produc	<u>ts</u>				Share of sales		
Raw ma					outs (raw materials, la any related company?		
	or any other service						
energy,	or any other service -Continue to questi	ion III-7b below.	☐ NoC	Continue to	question III-7c below		
energy, o Yes- Inputs f producti	-Continue to questi	sIn the space pryour firm receive	rovided below, i	identify th	e inputs used in the ose financial statemen		

${\bf PART~III.--\underline{FINANCIAL~INFORMATION}.-} \textit{Continued}$

Inputs from related firms at costAll intercompany profit on inputs <u>purchased from related parties</u> should be eliminated from the costs reported to the Commission in question III-10 (i.e., costs reported in question III-10, to the extent that they reflect inputs purchased from related parties, should only reflect the related party's cost and not include an associated profit component). Reasonable methods for determining and eliminating the associated profit on input purchased from related parties are acceptable.						
Has your firm complied with the Commission's instructions regarding costs associated with inputs purchased from related parties?						
Yes No—Plea	ase contact C	harles Yost	(202-205-3	432, Charles	.Yost@usite	c.gov).
question III-10, pleas particular expense/co a brief description of would include, but an	se indicate in ost line items the charges, re not limited	the schedule from questic and the asso to, items su	e below the son III-10 who ciated value ch as asset v	specific nonreceives (in \$1,000).	ecurring char lated charges . Nonrecurr	rges, the s are included, ing charges
		T				2010
lon-recurring charges: Ir	the far left co	lumn please p	provide a brief	f description of	each nonrect	urring charge
•				1		
	costs reported in que parties, should only recomponent). Reason purchased from related Has your firm compliants purchased from Yes No—Pleated Nonrecurring charge question III-10, please particular expense/coabrief description of would include, but and due to restructuring of the lon-recurring charges: Ir not indicate the particular expenses of the lon-recurring charges: Ir not indicate the particular expenses of the lon-recurring charges: Ir not indicate the particular expenses of the lon-recurring charges: Ir not indicate the particular expenses of the longest expenses of th	costs reported in question III-10, to parties, should only reflect the rel component). Reasonable methods purchased from related parties are. Has your firm complied with the compute purchased from related parties. Yes No—Please contact Company Nonrecurring charges.—For each question III-10, please indicate in particular expense/cost line items a brief description of the charges, would include, but are not limited due to restructuring of the company limited to the particular expense/cost. Item 2005	costs reported in question III-10, to the extent parties, should only reflect the related party's component). Reasonable methods for determing purchased from related parties are acceptable. Has your firm complied with the Commission inputs purchased from related parties? Yes No—Please contact Charles Yost Nonrecurring charges.—For each annual performance expense/cost line items from question a brief description of the charges, and the asson would include, but are not limited to, items surfue due to restructuring of the company's glycine Item 2005 2006 Item 2005 line item whe	costs reported in question III-10, to the extent that they ref parties, should only reflect the related party's cost and not component). Reasonable methods for determining and elipurchased from related parties are acceptable. Has your firm complied with the Commission's instruction inputs purchased from related parties? Yes No—Please contact Charles Yost (202-205-3). Nonrecurring charges.—For each annual period for which question III-10, please indicate in the schedule below the sparticular expense/cost line items from question III-10 who a brief description of the charges, and the associated value would include, but are not limited to, items such as asset with due to restructuring of the company's glycine operations. Calendary Item 2005 2006 2007 Ion-recurring charges: In the far left column please provide a brief and indicate the particular expense/cost line item where the associated and indicate the particular expense/cost line item where the associated and indicate the particular expense/cost line item where the associated and indicate the particular expense/cost line item where the associated and indicate the particular expense/cost line item where the associated and indicate the particular expense/cost line item where the associated and indicate the particular expense/cost line item where the associated and indicate the particular expense/cost line item where the associated and indicate the particular expense/cost line item where the associated and indicate the particular expense/cost line item where the associated and indicate the particular expense/cost line item where the associated and indicate the particular expense/cost line item where the associated and indicate the particular expense/cost line item where the associated and indicate the particular expense/cost line item where the associated and indicate the particular expense/cost line item where the associated and indicate the particular expense/cost line item where the associated and indicate the particular expense indicate the particular e	costs reported in question III-10, to the extent that they reflect inputs purparties, should only reflect the related party's cost and not include an ascomponent). Reasonable methods for determining and eliminating the purchased from related parties are acceptable. Has your firm complied with the Commission's instructions regarding inputs purchased from related parties? Yes No—Please contact Charles Yost (202-205-3432, Charles Nonrecurring chargesFor each annual period for which financial requestion III-10, please indicate in the schedule below the specific nonreparticular expense/cost line items from question III-10 where the associated brief description of the charges, and the associated values (in \$1,000) would include, but are not limited to, items such as asset write-offs and due to restructuring of the company's glycine operations. Calendar years ended-lem 1. Item 2005 2006 2007 2008 Item 2005 2006 2007 2008 Item 2005 2006 2007 2008	costs reported in question III-10, to the extent that they reflect inputs purchased fro parties, should only reflect the related party's cost and not include an associated procomponent). Reasonable methods for determining and eliminating the associated procomponent. Reasonable methods for determining and eliminating the associated procomponent. Reasonable methods for determining and eliminating the associated procomponent. Reasonable methods for determining and eliminating the associated procomponent. Proceedings are acceptable. Has your firm complied with the Commission's instructions regarding costs associated inputs purchased from related parties? Yes No—Please contact Charles Yost (202-205-3432, Charles.Yost@usite Nonrecurring chargesFor each annual period for which financial results are reproduestion III-10, please indicate in the schedule below the specific nonrecurring charger a brief description of the charges, and the associated values (in \$1,000). Nonrecurring abrief description of the charges, and the associated values (in \$1,000). Nonrecurring would include, but are not limited to, items such as asset write-offs and accelerated due to restructuring of the company's glycine operations. Calendar years ended Item 2005 2006 2007 2008 2009 Ion-recurring charges: In the far left column please provide a brief description of each nonrecund indicate the particular expense/cost line item where the associated charge is included in question indicate the particular expense/cost line item where the associated charge is included in question indicate the particular expense/cost line item where the associated charge is included in question indicate the particular expense/cost line item where the associated charge is included in question indicate the particular expense/cost line item where the associated charge is included in question indicate the particular expense/cost line item where the associated charge is included in question in the charges.

PART III.—FINANCIAL INFORMATION--Continued

III-10. Operations on glycine.—Report the revenue and related cost information requested below on the glycine operations of your U.S. establishment(s). Do not report resales of purchased glycine.

Note that internal consumption and transfers to related firms must be valued at fair market value and purchases from related firms must be at cost. Provide data on a calendar year basis for the six most recently completed years in chronological order from left to right. If your firm was involved in tolling operations (either as the toller or as the tollee) please contact Charles Yost (202-205-3432, Charles.Yost@usitc.gov) before completing this section of the questionnaire.

Quantity (in 1,000 pounds) and value (in \$1,000)						
Item	2005	2006	2007	2008	2009	2010
Net sales quantities: ³ Commercial sales						
Internal consumption						
Transfers to related firms						
Total net sales quantities						
Net sales values: ³ Commercial sales						
Internal consumption						
Transfers to related firms						
Total net sales values						
Cost of goods sold (COGS): ⁴ Raw materials, net of by-products						
Direct labor						
Other factory costs						
Total COGS						
Gross profit or (loss)						
Selling, general, and administrative (SG&A) expenses: Selling expenses						
General and administrative expenses						
Total SG&A expenses						
Operating income (loss)						
Other income and expenses: Interest expense						
All other expense items						
Continued Dumping and Subsidy Offset Act funds received ⁵						
All other income items						
All other income or expenses, net						
Net income or (loss) before income taxes						
Depreciation/amortization included above						

¹ Include only sales (whether domestic or export) and costs related to your <u>U.S. manufacturing operations</u>.

² Please eliminate any profits or (losses) on inputs from related firms pursuant to question III-7.

³ Less discounts, returns, allowances, and prepaid freight. The total quantities and values should approximate the corresponding total shipment quantities and values reported in Part II of this questionnaire.

⁴ COGS should include costs associated with sales, internal consumption and transfers to related firms.

⁵ Please report funds received under this act in the period(s) in which they were received. Do not report these funds as an offset to operating expenses.

PART III.—<u>FINANCIAL INFORMATION</u>--Continued

III-11. <u>Asset values.</u>--Report the total assets associated with the production, warehousing, and sale of glycine. If your firm does not maintain some or all of the specific asset data in the normal course of business, please estimate it based upon some rational method (such as production, sales, or costs) that is consistent with your cost allocations in the previous question. Your finished goods inventory value should reconcile with the inventory quantity data reported in Part II. Provide data as of the end of your six most recently completed fiscal years in chronological order from left to right.

	Value (<i>in \$1,000</i>)						
Item	<u>2005</u>	<u>2006</u>	2007	2008	<u>2009</u>	<u>2010</u>	
ASSETS associated with the production, warehousing, and sale of product: 1. Current assets: A. Cash and equivalents							
B. Accounts receivable, net							
C. Finished goods inventories							
D. All other (describe:)							
E. Total current assets (lines 1.A. through 1.D.)							
Property, plant, and equipment A. Original cost of property, plant, and equipment							
B. Less: Accumulated depreciation							
C. Equals: Book value of property, plant, and equipment							
3. Other (describe:)							
Total assets (lines 1.E., 2.C., and 3)							

III-12. <u>Capital expenditures and research and development expenses.</u>--Report your firm's capital expenditures and research and development expenses on glycine. Provide data on a calendar year basis for the six most recently completed years in chronological order from left to right.

			Value (i	n \$1,000)		
		Calendar year				
Item	2005	2006	2007	2008	2009	<u>2010</u>
Capital expenditures						
Research and development expenses						

PART IV.--PRICING AND MARKET FACTORS

Further information on this part of the questionnaire can be obtained from Aimee Larsen (202-205-3179, Aimee.Larsen@usitc.gov).

IV-1.	Please identify the individual to b part IV?	e contacted regarding the confidential information requested in
	Name and title:	
	•	ich Commission staff may contact the individual responsible for the submitted confidential information.
	E-mail:	Telephone: ()
	Fax: ()	

PRICE DATA

This section requests quarterly quantity and value data, f.o.b. your U.S. point of shipment, for your commercial shipments to unrelated U.S. customers since 2005 of the following products produced by your firm.

- <u>Product 1</u>.-- Pharmaceutical-grade glycine A white, odorless, crystalline powder with a sweet taste, having an assay (glycine content) of 98.5 percent to 101.5 percent (dry basis), and with no more than 70 ppm chloride, no more than 65 ppm sulfate, and no more than 10 ppm heavy metals.
- <u>Product 2.-- USP-grade</u> glycine A white, odorless, crystalline powder with a sweet taste, having an assay (glycine content) of 98.5 percent to 101.5 percent (dry basis), and with no more than 70 ppm chloride, no more than 65 ppm sulfate, no more than 20 ppm heavy metals, and not otherwise qualifying as pharmaceutical-grade glycine.
- <u>Product 3.--Technical-grade</u> glycine A white, off-white, or slightly yellow crystalline powder, having an assay (glycine content) of 98.5 percent to 101.5 percent (dry basis), with no more than 200 ppm sulfates, and not otherwise qualifying as USP-grade glycine.

Note.—The pricing product data should reflect the end use for which the glycine in question is sold. The purity requirements listed for each pricing product reflect minimum purity requirements for end users in those markets. Any glycine that could be sold into a higher purity end use but is not should be recorded as a sale to the market into which it is sold. For example, if a producer produces glycine meeting the specifications for use in deodorant applications (USP grade) but sells that product for metal complexing (technical grade), that sale should be recorded as a technical grade sale.

Please note that total dollar values should be f.o.b., U.S. point of shipment and should not include U.S.-inland transportation costs. Total dollar values should reflect the *final net* amount paid to you (i.e., should be net of all deductions for discounts or rebates). See instruction booklet.

IV-2. **Pricing data.--**Report below the quarterly price data¹ for pricing products² produced and sold by your firm.

	(Quantity <i>in p</i> e		Prod	uct 3		
Period of shipment	Quantity	Value	Quantity	Value	Quantity	Value
2005:	Quantity	Value	Quantity	Valuo	Quantity	Value
January-March						
April-June						
July-September						
October-December						
2006:						
January-March						
April-June						
July-September						
October-December						
2007:						
January-March						
April-June						
July-September						
October-December						
2008:						
January-March						
April-June						
July-September						
October-December						
2009:						
January-March						
April-June						
July-September						
October-December						
2010:						
January-March						
April-June						
July-September						
October-December	- :					1
¹ Net values (<i>i.e.</i> , gross sales value returned goods), f.o.b. your U.S. point of	of shipment.			s, prepaid fre	eight, and the v	alue of
² Pricing product definitions are pro	ovided on the fi	rst page of I	Part IV.			
Note If your product does not exactly provide a description of your product:	meet the produ	uct specifica	tions but is co	mpetitive wi	th the specified	d product,
Product 1:						
Product 2:						

(che		m issues price lists, please	hat it charges for sales of glycine e include a copy of a recent price list y submit some sample pages.
	Γransaction by transaction	☐ Contracts	Set price lists
	OtherPlease describe:		
Disc		e and describe your firm's	s discount policies (check all that
	Quantity discounts [Annual total volume di	iscounts
	OtherPlease describe:		
Pric	ing terms for glycine		
(a)	•		sproduced glycine (e.g., 2/10 net 30
(b)	On what basis are your promised in F.o.bPlease specify		usually quoted? (check one) Delivered
glyc 12 n	ine in 2010 were on a (1) lon	g-term contract basis (mu ct basis (multiple deliveri	firm's sales of its U.Sproduced ltiple deliveries for more than es up to and including 12 months), and
	Type of sale	Share of sal	es (percent)
	Type of sale Long-term contracts	Share of sal	es (percent)
		Share of sal	es (percent)

IV-7.	Long-term contract provisionsIf you sell on a long-term contract basis, please answer the							
	following questions with respect to provisions of a typical long-term contract.							
	(a)	What is the average	ge duration	of a contract?				
	(b)	Can prices be rene	egotiated d	uring the contra	act period?	Yes	☐ No	
	(c)	Does the contract	fix quantit	y, price, or both	n? 🗌 Quan	tity [Price	Both
	(d)	Does the contract	have a me	et or release pro	ovision?	Yes	☐ No	
IV-8.		term contract prov ng questions with r						answer the
	(a)	What is the average	ge duration	of a contract?				
	(b)	Can prices be rene	egotiated d	uring the contra	act period?	Yes	☐ No	
	(c)	Does the contract fix quantity, price, or both? Quantity Price Both						
	(d)	Does the contract have a meet or release provision? Yes No						
IV-9.		imesWhat is the r firm's sales of yo				's order aı	nd the date	of delivery
		Source	<u>S</u>	hare of sales in	<u>2010</u>	<u>]</u>	Lead time	
	From	inventory						
	Produ	ced to order						
	Total			100 %				
IV-10.	Shipping information							
	(a)	What is the approximate percentage of the total delivered cost of glycine that is accounted for by U.S. inland transportation costs? percent.						
	(b)	Who generally arr		•	o your custo	mers' loca	tions? (ch	eck one)
	(c)	What proportion of percent. W		es are delivered to 1,000 miles?				

PART IV.--PRICING AND MARKET FACTORS--Continued

IV-11. <u>Geographical shipments.--</u> What is the geographic market area in the United States served by your firm's glycine? (check all that apply)

	Geographic area	√ if applicable
	NortheastCT, ME, MA, NH, NJ, NY, PA, RI, and VT.	
	MidwestIL, IN, IA, KS, MI, MN, MO, NE, ND, OH, SD, and WI.	
	SoutheastAL, DE, DC, FL, GA, KY, MD, MS, NC, SC, TN, VA, and WV.	
	Central SouthwestAR, LA, OK, and TX.	
	MountainsAZ, CO, ID, MT, NV, NM, UT, and WY.	
	Pacific CoastCA, OR, and WA.	
	Other .—All other markets in the United States not previously listed, including AK, HI, PR, VI, among others.	
IV-12.	Changes in end usesHave there been any changes in the end uses of glycin	e since 2005?
	☐ No ☐ YesPlease describe.	
IV-13.	Anticipated changes in end usesDo you anticipate any changes in terms of glycine in the future? No YesPlease describe and identify the time period	f the end uses of
IV-14.	Pharmaceutical grade glycine.—Please describe and comment on the market grade glycine. How is it different from the market for USP grade glycine? We to entry into this market? What is the role of government regulation in setting standards?	That are the barriers

	ibstitute roduct	Description of applications and end uses in which this substitute can be used	Have changes in the prices of this substitute affected the price of glycine since January 1, 2005? Please explain.
1.			☐ No
2.			☐ No
3.			☐ No ☐ Yes ☐
IV-16.		substitutesHave there be ituted for glycine since 200 YesPlease explain	
IV-17.	Anticipated substitutabil	I changes in substitutes lity of other products for gl	

IV-18.	Raw materials.—						
	(a)	To what extent have changes in the prices of raw materials affected your firm's selling prices for glycine since 2005?					
	(b)	Do you entisingted changes in your ray, material costs in the foreseasable future?					
	(b)	Do you anticipated changes in your raw material costs in the foreseeable future? No YesPlease explain.					
IV-19.		ges in factors affecting supplyHave any changes occurred in any other factors affecting					
	produc	(e.g., changes in availability or prices of energy or labor; transportation conditions; etion capacity and/or methods of production; technology; export markets; or alternative etion opportunities) that affected the availability of U.Sproduced glycine in the U.S. t since 2005?					
	□ No	YesPlease note the time period(s) of any such changes, the factors(s) involved, and the impact such changes had on your shipment volumes and prices.					
IV-20.	Availability of supply (U.Sproduced)						
	(a)	Do you anticipate any changes in terms of the availability of U.Sproduced glycine in the U.S. market in the future?					
		☐ Increase ☐ No change ☐ Decrease					
	(b)	If you anticipate changes in supply, please explain.					

IV-21.	<u>Availability of supply (nonsubject)</u> Has the availability of <u>NONSUBJECT</u> glycine (<i>i.e.</i> , glycine imported from countries other than China) changed since 2005?				
	☐ No ☐ YesPlease explain.				
IV-22.	Export constraints. Can your firm shift its sales of glycine between the U.S. market and alternative country markets?				
	□ No □ Yes				
	Please describe any contracts, other sales arrangements, or other constraints that would prevent or retard your firm from shifting glycine between the U.S. and alternative country markets within a 12-month period.				
IV-23.	<u>Product changes</u> Have there been any significant changes in the product range, product mix, or marketing of glycine since 2005?				
	☐ No ☐ YesPlease describe and quantify if possible for each grade of glycine for which you are answering "Yes."				
	9				
IV-24.	Anticipated product changesDo you anticipate any changes in terms of the product range, product mix, or marketing of glycine in the future?				
	☐ No ☐ YesPlease identify, including the time period.				

IV 25	Demand trends	

	(a)	How has the demand within the United States for glycine changed since January 1, 200. What principal factors affect changes in demand?			ed since January 1, 2005?
		☐ Increased	☐ No Change	Decreased	Fluctuated
(b) How has the demand outside the United States (if known) for glycine chan January 1, 2005? What principal factors affect changes in demand?					
		☐ Increased	☐ No Change	Decreased	Fluctuated
IV-26.	IV-26. Anticipated demand trends.—				
	(a)	How do you anticipate demand will change within the United States for glycine in the future? What principal factors will affect these changes in demand?			
		☐ Increase	☐ No Change	Decrease	Fluctuate
	(b) How do you anticipate demand will change outside the United States for glycine in future? What principal factors will affect these changes in demand?				
		Increase	☐ No Change	Decrease	Fluctuate

IV-27.	<u>Condi</u>	tions of competition	
	(a)	Is the glycine market subject to business cycles or conditions of competition other than the changes in the overall economy?	
		☐ No ☐ YesPlease explain and estimate the duration of any such cycle.	
	(b)	Have the business cycles or conditions of competition for glycine changed since 2005?	
		No YesPlease explain any such changes.	
IV-28.	IV-28. <u>Supply constraints.</u> Has your firm refused, declined, or been unable to supply glycined January 1, 2005? (Examples include placing customers on allocation or "controlled or declining to accept new customers or renew existing customers, delivering less than the promised, unable to meet timely shipment commitments, etc.).		
	No	Yes Please note and document the time period(s) (i.e., month and year), the customer involved, the amount and type of product involved; and the reason for the allocation.	
IV-29.		omparisons.—How do the market prices of glycine in the U.S. compare with non-U.S. s, if known? Provide specific information as to time periods and regions for any price risons.	
☐ U	.S. mark	et prices are higher	

IV-30.	Market studiesPlease provide as a separate attachment to this request any studies, surveys, etc that you are aware of that quantify and/or otherwise discuss glycine supply (including production capacity and capacity utilization) and demand in (1) the United States, (2) each of the other major producing/consuming countries, including China, and (3) the world as a whole. Of particular interest is such data from 2005 to the present and forecasts for the future.			
IV-31. Barriers to trade. Are your exports of glycine subject to any tariff or non-tariff bin other countries?				
	□ No □ Yes	Please list the countries and describe significant changes in such barriers that are expected to occur in the further	s that have occurred since 2005, or	
IV-32.	interchangeable (<i>i.e.</i> , can below, using "A" to indicinterchangeable, "F" to in that the products are <i>some</i>	glycine produced in the United States they physically be used in the same cate that the products from a specifie adicate that the products are <i>frequent etimes</i> interchangeable, "N" to indic to indicate <i>no familiarity</i> with products	applications)? Please indicate d country-pair are <i>always</i> tly interchangeable, "S" to indicate ate that the products are <i>never</i>	
	Country-pair	China	Other countries	
	United States			
	China			
	¹ For any country-pair p the factors that limit or pred	oroducing glycine that is sometimes or no clude interchangeable use:	ever interchangeable, please explain	

IV-33. **Factors other than price.**--Are differences other than price (*i.e.*, quality, availability, transportation network, product range, technical support, *etc.*) between glycine produced in the United States and in other countries a significant factor in your firm's sales of the products? Please indicate below, using "A" to indicate that such differences are *always* significant, "F" to indicate that such differences are *frequently* significant, "S" to indicate that such differences are *sometimes* significant, "N" to indicate that such differences are *never* significant, and "0" to indicate *no familiarity* with products from a specified country-pair.¹

Country-pair	China	Other countries
United States		
China		
¹ For any country-pair your firm's sales of glycing by such factors:	for which factors other than price <i>always</i> e, identify the country-pair and report the	or frequently are a significant factor in advantages or disadvantages imparted